Penn-BioNTech Innovative Therapeutics Seed Fund Reveals Its First Investment to Advance Therapeutic Innovation
The Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund) has announced its investment in Emvena Therapeutics, a biotechnology company developing innovative messenger RNA (mRNA) medicines designed to deliver therapeutic treatments directly to the placenta. The company’s technology aims to address serious maternal and fetal health conditions, including preeclampsia, a pregnancy-related complication associated with significant risks to mothers and babies.
The investment marks an important milestone for both Emvena Therapeutics and the PxB Fund, as the biotechnology company becomes the fund’s first launched and financed venture. Established to accelerate the translation of promising research from the University of Pennsylvania into innovative healthcare solutions, the PxB Fund supports the development of early-stage biotechnology companies seeking to address significant unmet medical needs.
Emvena is building its therapeutic development strategy around placenta-targeted mRNA delivery technology originating from research conducted at the University of Pennsylvania. Its lead development program focuses on preeclampsia, a serious gestational condition affecting an estimated 2%–8% of pregnancies worldwide. The disease is a major contributor to maternal and infant illness and mortality, with limited treatment options currently available to address its underlying biological causes.
Through its placenta-targeted delivery platform, Emvena aims to develop treatments capable of reaching the placenta and influencing biological processes associated with pregnancy complications. The company’s initial research foundation suggests that targeted mRNA delivery could provide a new therapeutic approach for conditions that have historically received limited attention from pharmaceutical and biotechnology drug development programs.
The proceeds from the seed financing will support the advancement of Emvena’s lead preeclampsia program toward investigational new drug (IND)-enabling studies. The funding will also help expand the company’s placenta-targeted mRNA platform into additional maternal and fetal health indications.
PxB Fund Selects Emvena as Its First Biotechnology Investment
The investment represents the first company formation and financing initiative undertaken by the Penn-BioNTech Innovative Therapeutics Seed Fund. The fund was established to support the development and commercialization of promising scientific discoveries emerging from the University of Pennsylvania, with an emphasis on translating innovative research into potential treatments for patients.
By investing in Emvena, the PxB Fund is supporting the advancement of research developed through the laboratory of Michael J. Mitchell, PhD, the Hibbert Professor of Bioengineering in the University of Pennsylvania’s School of Engineering and Applied Science.
The fund aims to identify scientific innovations with the potential to address significant healthcare challenges and provide the resources required to transform early-stage discoveries into biotechnology companies.
Anna Turetsky, PhD, General Partner of the PxB Fund, highlighted the importance of Emvena’s scientific foundation and its potential to address an underserved area of medicine.
“Emvena represents the kind of company the PxB Fund intends to catalyze and help build: one translating important Penn science into potential treatments for a serious medical need that has received inadequate attention,” said Dr. Turetsky.
She added that the fund is proud to make Emvena its first investment and looks forward to supporting additional innovations originating from the University of Pennsylvania as they progress toward clinical development and ultimately patients.
The launch of Emvena demonstrates the PxB Fund’s strategy of combining institutional research capabilities with biotechnology entrepreneurship and investment support. By creating a dedicated company around the placenta-targeted delivery technology, the fund seeks to establish a pathway for further development of mRNA-based treatments for maternal and fetal conditions.
University of Pennsylvania Research Provides Scientific Foundation
Founded in 2026, Emvena Therapeutics is developing its technology based on research conducted in the laboratory of Michael J. Mitchell, PhD, at the University of Pennsylvania.
The foundational research, published in the scientific journal Nature, demonstrated the potential of a novel lipid nanoparticle (LNP) formulation to deliver mRNA preferentially to the placenta compared with conventional lipid nanoparticle delivery systems.
Lipid nanoparticles are specialized delivery vehicles widely used in mRNA-based therapeutics. They protect fragile mRNA molecules from degradation and help transport them into cells, where the genetic instructions can be used to produce specific proteins.
Although LNP technology has become an important component of modern drug development, achieving delivery to specific organs and tissues remains a significant challenge. Conventional delivery systems may distribute therapeutic material across multiple tissues, potentially limiting the amount of active mRNA reaching the intended target.
The research conducted by the Mitchell laboratory explored an alternative approach designed to improve delivery selectivity toward the placenta.
The findings demonstrated that the novel LNP formulation preferentially delivered mRNA to placental tissue compared with conventional LNPs. This tissue-targeting capability could provide an important foundation for developing treatments intended to influence biological processes occurring within the placenta.
The research team also investigated the therapeutic potential of delivering mRNA encoding vascular endothelial growth factor (VEGF), a protein involved in blood vessel formation and development.
VEGF plays an important role in angiogenesis, the biological process through which new blood vessels develop from existing vascular structures. Proper blood vessel formation and function are essential during pregnancy because the placenta depends on an effective vascular network to support the exchange of oxygen, nutrients, and other essential substances between the mother and developing fetus.
In mouse models of preeclampsia, the researchers demonstrated that delivery of mRNA encoding VEGF reduced disease severity.
These preclinical findings provide an important scientific rationale for Emvena’s development strategy. By delivering mRNA directly to the placenta, the company aims to influence disease-related biological pathways at the site where important pregnancy processes occur.
However, additional research and development will be necessary to establish the safety, efficacy, dosing requirements, and clinical potential of this approach in humans.
Targeting Preeclampsia Through Placenta-Directed mRNA Medicines
Preeclampsia is a serious pregnancy complication characterized by high blood pressure that develops during pregnancy, often after 20 weeks of gestation. The condition can also involve abnormalities affecting multiple organs, including the kidneys, liver, and cardiovascular system.
In severe cases, preeclampsia can lead to life-threatening complications for both the mother and the baby. Potential consequences include maternal organ damage, seizures, restricted fetal growth, premature birth, and other serious pregnancy-related outcomes.
The condition is also associated with abnormalities in placental development and function. Problems involving placental blood vessel formation and vascular regulation can contribute to impaired blood flow and the development of disease-related complications.
Despite advances in prenatal monitoring and obstetric care, there is currently no approved therapy that directly addresses the underlying disease mechanisms of preeclampsia.
Clinical management generally focuses on monitoring maternal and fetal health, controlling blood pressure, preventing complications, and determining the safest timing for delivery.
In severe cases, early delivery may become necessary when continuing the pregnancy poses a substantial risk to the mother’s health or the developing baby. However, premature delivery can introduce additional health challenges, particularly when it occurs significantly before the expected delivery date.
This creates a substantial unmet medical need for treatments capable of addressing the underlying biological mechanisms of preeclampsia while potentially supporting a safer continuation of pregnancy.
Emvena aims to address this challenge through its placenta-targeted mRNA platform.
By delivering therapeutic mRNA directly to placental tissue, the company hopes to enable localized production of proteins that could influence disease-associated biological pathways. The approach is intended to provide a more targeted therapeutic strategy than conventional treatments that primarily manage symptoms.
Young T. Kwon, PhD, Chief Executive Officer and Executive Chair of Emvena Therapeutics, emphasized the limitations of current preeclampsia management and the potential of the company’s scientific approach.
“Preeclampsia has long been managed by treating symptoms and, when the mother’s health is at risk, delivering the baby early – often much earlier than is ideal,” said Dr. Kwon.
He noted that research emerging from the Mitchell laboratory offers a potential new approach to delivering medicines directly to the placenta, where important disease-related processes occur.
“Our goal is to build Emvena into a company that can bring meaningful new treatment options to mothers, babies, and the physicians who care for them,” he added.
The company’s development strategy is focused on exploring whether targeted mRNA medicines can provide new therapeutic opportunities for pregnancy-related disorders where conventional treatment approaches remain limited.
Seed Financing to Support IND-Enabling Development
The proceeds from the PxB Fund’s seed investment will support the advancement of Emvena’s lead preeclampsia program toward IND-enabling studies.
IND-enabling development represents an important stage in the drug development process. Before a biotechnology company can initiate clinical testing in humans in the United States, it generally needs to generate sufficient preclinical evidence and complete the necessary regulatory documentation to support an investigational new drug application.
For Emvena, this stage is expected to involve further evaluation of its placenta-targeted mRNA technology, including relevant preclinical studies required to assess the therapeutic candidate’s safety and development potential.
The investment will also support the expansion of the company’s platform into additional maternal and fetal health indications.
This broader strategy reflects the potential applicability of placenta-targeted delivery technology beyond a single pregnancy complication. The placenta plays a central role in fetal development, maternal-fetal exchange, and pregnancy maintenance. Consequently, therapeutic approaches capable of selectively delivering medicines to placental tissue could potentially be investigated across multiple conditions involving placental dysfunction.
Nevertheless, each potential indication will require disease-specific research to establish its biological rationale and therapeutic suitability.
The company’s immediate priority remains advancing its lead program for preeclampsia while building the scientific and operational capabilities necessary to support a broader development pipeline.
Experienced Scientific and Biotechnology Leadership Team
Emvena’s founding team combines expertise in bioengineering, mRNA delivery, maternal healthcare, clinical development, and biotechnology company leadership.
The team includes researchers who contributed to the development of the underlying placenta-targeted technology, alongside experienced clinical and business leaders who bring expertise in advancing therapeutic programs.
Michael J. Mitchell, PhD, serves as scientific co-founder and advisor. He is the Hibbert Professor of Bioengineering at the University of Pennsylvania’s School of Engineering and Applied Science. His laboratory developed the foundational research supporting Emvena’s placenta-targeted LNP technology.
Kelsey L. Swingle, PhD, is a scientific co-founder and advisor and currently serves as an assistant professor of bioengineering at Rice University. She contributed to the development of the technology during her doctoral research in the Mitchell laboratory.
Hannah Safford, PhD, is a scientific co-founder and Director of Research and Development at Emvena. She also helped develop the underlying technology while completing her doctoral studies in the Mitchell laboratory. Her role at the company will support the continued scientific development and advancement of the platform.
Allison August, MD, serves as co-founder and Senior Clinical Advisor. She is an obstetrician-gynecologist with 25 years of clinical and drug development experience. Her professional background includes senior leadership positions at Comanche Biopharma and Moderna. Her clinical and pharmaceutical development experience brings an important perspective to Emvena’s efforts to develop treatments for maternal and fetal conditions.
Young T. Kwon, PhD, serves as co-founder, Chief Executive Officer, and Executive Chair. He brings biotechnology operating and leadership experience, including senior positions at Momenta Pharmaceuticals and Alchemab Therapeutics. Dr. Kwon also serves as an advisor to the PxB Fund, connecting his biotechnology leadership experience with the fund’s broader mission of translating promising research into therapeutic companies.
The combination of scientific researchers, clinical specialists, and experienced biotechnology executives provides Emvena with expertise across the different stages of therapeutic development, from early research and platform validation to clinical strategy and company building.
Advancing Innovation in Underserved Maternal and Fetal Healthcare
Emvena’s launch and initial financing highlight growing interest in developing innovative treatments for maternal and fetal health conditions that have historically received comparatively limited investment in pharmaceutical research.
Although pregnancy-related disorders can have serious consequences for mothers and developing babies, therapeutic development in this area faces unique scientific and clinical challenges. Drug developers must consider not only the potential benefits for the mother but also the safety implications for the developing fetus and the placenta.
These considerations make tissue-specific delivery technologies particularly relevant to maternal healthcare research.
Emvena’s approach seeks to address some of these challenges by focusing on the placenta as the intended site of therapeutic delivery. The underlying research provides an initial scientific foundation for evaluating whether targeted mRNA delivery can influence biological pathways associated with pregnancy complications.
The company’s first program in preeclampsia represents an effort to move beyond symptom management toward potential therapies that address disease-related mechanisms.
With financial support from the PxB Fund, Emvena plans to advance its lead program toward IND-enabling development while exploring additional opportunities for its platform.
The investment also represents the beginning of the PxB Fund’s broader initiative to support University of Pennsylvania research with commercial and clinical potential.
As Emvena progresses, further preclinical validation and regulatory development will be necessary before its investigational medicines can enter human clinical trials. The company’s ability to demonstrate safe and effective placenta-targeted delivery will be an important factor in determining the future potential of its technology.
Through its initial investment in Emvena, the PxB Fund is supporting an emerging biotechnology company focused on addressing a significant unmet medical need. The combination of University of Pennsylvania research, targeted mRNA delivery technology, and experienced biotechnology leadership provides the foundation for Emvena’s development efforts.
Ultimately, the company’s goal is to develop new therapeutic options for preeclampsia and other maternal and fetal conditions, potentially creating new opportunities for mothers, babies, and healthcare professionals managing complex pregnancy-related disorders.
About Emvena Therapeutics
Emvena Therapeutics, Inc is a biotechnology company developing placenta-targeted mRNA medicines for serious maternal and fetal conditions. Founded in 2026 based on research from the University of Pennsylvania, the company is advancing a novel lipid nanoparticle platform designed to preferentially deliver mRNA to the placenta. Emvena’s lead program targets preeclampsia, a serious pregnancy complication with significant unmet medical need. Based in Philadelphia, Emvena is backed by the Penn-BioNTech Innovative Therapeutics Seed Fund. For more information, visit www.emvenatx.com.
About the Penn-BioNTech Innovative Therapeutics Seed Fund
The PxB Fund is a $50 million venture capital fund formed by the University of Pennsylvania, BioNTech SE, and Osage University Partners (“OUP”) to invest in early-stage life science companies based on Penn intellectual property and/or founded by Penn researchers. The fund focuses on seed and Series A investments in therapeutics, platforms, diagnostics, and research tools emerging from Penn’s faculty and researcher community.
The fund helps Penn investigators translate promising biomedical discoveries and advance them to improve human health and address serious medical conditions. The PxB Fund is managed by OUP, a Philadelphia-based venture capital firm with over $800 million under management that has invested in more than 150 startups commercializing university research, including more than 10 Penn startups.